Albuterol Pediatric Dose — Asthma & Respiratory
Albuterol is a short-acting beta-2 adrenergic agonist that produces rapid bronchodilation through relaxation of airway smooth muscle. It is the cornerstone rescue agent for acute bronchospasm and moderate-to-severe asthma exacerbations in pediatric patients. Both intermittent and continuous nebulized delivery are supported in current pediatric acute care practice.
Pediatric Dosing
Continuous Aerosolized Nebulization
Initiate at 0.5 mg/kg/hour, titrating upward by 0.25 mg/kg/hour as clinically indicated. Maximum: 40 mg/hour regardless of weight.
Worked example — continuous: For a 20 kg child, starting dose = 20 × 0.5 mg/kg/hr = 10 mg/hr. First uptitration step = 20 × 0.25 mg/kg/hr = 5 mg/hr increase → 15 mg/hr.
Intermittent Nebulization
- ≤ 20 kg: 2.5 mg per treatment
- > 20 kg: 5 mg per treatment
Worked example — intermittent: A 15 kg child receives 2.5 mg per nebulized treatment; a 25 kg child receives 5 mg per treatment. Frequency should be guided by clinical response and institutional protocol.
Indications and Clinical Context
Nebulized albuterol is indicated for acute bronchospasm associated with asthma exacerbations, reactive airway disease, and bronchiolitis with significant bronchospasm in pediatric patients. Intermittent dosing is appropriate for mild-to-moderate exacerbations, while continuous nebulization is reserved for moderate-to-severe exacerbations or patients failing intermittent therapy. PALS and NAEPP guidelines support continuous albuterol as an escalation strategy when repeated intermittent treatments provide insufficient relief.
Continuous nebulization is typically initiated in monitored settings such as the pediatric emergency department or PICU, where close cardiorespiratory surveillance is feasible. The weight-based dosing strategy for continuous delivery allows individualized titration, while the fixed-dose approach for intermittent nebulization reflects standard clinical practice for this age group.
Administration and Monitoring
Albuterol is delivered via the inhalation route using a standard or high-flow nebulizer circuit. Continuous nebulization requires a calibrated nebulizer pump to ensure accurate mg/hour delivery; consult institutional protocol for specific device setup. The maximum continuous dose of 40 mg/hour should not be exceeded. Monitor continuously for tachycardia, tremor, hypokalemia, and worsening hypoxia during high-dose or continuous therapy. Baseline and serial electrolytes (particularly potassium) are recommended during prolonged continuous nebulization given the risk of beta-2–mediated hypokalemia.
- Route: Inhaled nebulization only per this dosing reference
- Continuous max: 40 mg/hour — do not exceed regardless of weight
- Key adverse effects: Tachycardia, tremor, hypokalemia, paradoxical bronchospasm (rare)
- Monitoring: Continuous cardiorespiratory monitoring, oxygen saturation, and periodic electrolytes recommended for continuous therapy
- Contraindications/cautions: Use with caution in patients with pre-existing tachyarrhythmias; consult institutional protocol for additional contraindications
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.